While genetic disorders comprising overgrowth and neurological symptoms give a clear rationale for the application of PI3K/mTOR inhibitors in oncology, the prediction of sensitivity or resistance is still subject to discussion and evaluation. This evidence concerns the gene PIK3CD and hereditary disease.